Perfuse Therapeutics, a seed-stage company, was founded with the core mission of developing novel therapies to reduce blindness by improving retinal perfusion. The company's vision is to address the unmet needs in treating retinal diseases, starting with glaucoma. Perfuse Therapeutics focuses on creating innovative products that enhance blood flow to the retina, aiming to mitigate the effects of conditions like glaucoma and diabetic retinopathy, which are leading causes of blindness globally.
The company boasts a leadership team with significant expertise in ophthalmology and therapeutic development. Notable achievements include advancing their unique mechanism for retinal perfusion improvement and securing early-stage funding to support their research and development efforts. Perfuse Therapeutics has made a substantial impact by targeting critical gaps in current eye disease treatments, positioning itself as a promising player in the field of ocular health.
